Instituto de Medicina Molecular y Ciencias Avanzadas, Mexico City 01900, Mexico.
Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, MOR 62209, Mexico.
Biomolecules. 2019 Mar 14;9(3):102. doi: 10.3390/biom9030102.
Flavonoids are naturally occurring compounds that show health benefits on the liver. However, there is little investigation about identification and evaluation of new flavonoid-containing drugs for cholestatic liver disease, one of the most common liver illnesses. We aimed to a systematic search regarding efficacy of flavonoids for treatment of cholestatic liver disease, and then evaluate naringenin (NG) as representative flavonoid in an obstructive cholestasis model. We searched for information of experimental and clinical studies in four major databases without time and language limits. Intervention was defined as any flavonoid derivate compared with other flavonoid, placebo, or without comparator. In addition, we evaluated NG on a bile duct-ligated model in order to contribute evidence of its actions. Eleven experimental reports that support the efficacy of flavonoids in cholestatic liver disease were identified. However, there was no homogeneity in efficacy endpoints evaluated and methodology. On the other hand, NG showed beneficial effects by improving specific metabolic (cholesterol and lipoproteins) and liver damage (bilirubin and alkaline phosphatase) biomarkers. The review lacks homogeneous evidence about efficacy of flavonoids in experimental settings, and is susceptible to risk for bias. NG only showed improvements in specific disease biomarkers. More investigation is still needed to determine its potential for drug development.
类黄酮是天然存在的化合物，对肝脏健康有益。然而，对于胆汁淤积性肝病（最常见的肝病之一），很少有关于鉴定和评估新的含类黄酮药物的研究。我们旨在系统地搜索类黄酮治疗胆汁淤积性肝病的疗效，然后评估柚皮素（NG）作为代表性的类黄酮在梗阻性胆汁淤积模型中的作用。我们在四个主要数据库中进行了无时间和语言限制的实验和临床研究信息检索。干预定义为与其他类黄酮、安慰剂或无对照比较的任何类黄酮衍生物。此外，我们还评估了 NG 在胆管结扎模型中的作用，以提供其作用的证据。确定了 11 项支持类黄酮在胆汁淤积性肝病中疗效的实验报告。然而，评估的疗效终点和方法没有一致性。另一方面，NG 通过改善特定的代谢（胆固醇和脂蛋白）和肝损伤（胆红素和碱性磷酸酶）生物标志物显示出有益的效果。该综述缺乏关于类黄酮在实验环境中疗效的一致性证据，并且容易受到偏倚的风险。NG 仅在特定疾病生物标志物方面显示出改善。仍需要进一步研究以确定其药物开发的潜力。
